|Bid||39.74 x 800|
|Ask||39.78 x 1100|
|Day's range||38.66 - 40.00|
|52-week range||22.51 - 61.69|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.29|
Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder.
The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker?
From dealing with pain to improving mental health and even creating new natural health supplements, psychedelics are about to go mainstream in a major way